SNOA · Sonoma Pharmaceuticals, Inc.

Sonoma Pharmaceuticals operates in the niche hypochlorous acid (HOCl) healthcare segment, developing non-toxic products for dermatology, wound care, eye care, animal health, and disinfection with 22 FDA clearances and CE marking under EU MDR. The company relies heavily on international distribution partners across 55+ countries and U.S. channels including hospitals, DTC, and retailers like Amazon, avoiding heavy direct sales infrastructure. This partner-driven model supports broad reach but exposes Sonoma to distribution risks and limits pricing control. Financially, the balance sheet shows strain: actual cash of $2.56M and equity of $3.43M as of December 31, 2025, dwarfed by $10.19M liabilities and massive accumulated deficit of $200.4M, triggering a going concern warning from auditors Frazier & Deeter. Pro forma adjustments reflect minor ATM sales, but the offering catapults cash to $7.2M and equity to $8.1M, providing ~18 months runway assuming historical burn rates embedded in MD&A references. The $5M unit offering at $2.47—Nasdaq closing price on March 18, 2026—comprises 2.02M units (common shares or pre-funded warrants + 5-year warrants at 100% of unit price), with 15% overallotment and 5% underwriter warrants to Dawson James exercisable at 110% after 6 months. Proceeds fund working capital amid liquidity crunch, but investors face $0.36/share dilution on pro forma $2.00 NTBV, pushing post-money shares to 3.82M from 1.73M actual. Management lock-up for 90 days and insider ownership at 2.3% signal alignment, though repeated reverse splits (latest 1:20 in 2024) underscore chronic dilution. Key risks center on Nasdaq compliance amid $5M MVLS rule, execution in partner-dependent sales, and manufacturing reliance on Guadalajara facility. CEO Amy Trombly (since 2019) and CFO Jerry Dvonch lead a lean team with board tenure like Lead Director McLaughlin (since 2014). Governance includes Delaware Section 203 protections and blank-check preferred stock, potentially deterring takeovers. For investors, this offering addresses immediate survival but highlights transition needs in a competitive HOCl-disinfectant market where Sonoma's regulatory moat and clinical safety record (no serious adverse events) provide defensibility, yet profitability remains elusive without disclosed revenue trajectory.